Nov 19, 2021 7:00am EST Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
Nov 01, 2021 7:00am EDT Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Oct 21, 2021 7:00am EDT Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
Oct 13, 2021 7:00am EDT Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Oct 08, 2021 7:00am EDT Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Sep 22, 2021 7:30am EDT Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study
Sep 22, 2021 7:00am EDT Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors
Sep 20, 2021 7:00am EDT Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Sep 09, 2021 11:46am EDT Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
